ID   SiSo
AC   CVCL_2193
SY   SISO
DR   CLO; CLO_0009021
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470956
DR   BioSample; SAMN03473350
DR   cancercelllines; CVCL_2193
DR   Cell_Model_Passport; SIDM00394
DR   ChEMBL-Cells; CHEMBL3307272
DR   ChEMBL-Targets; CHEMBL613527
DR   Cosmic; 1995628
DR   Cosmic-CLP; 1240212
DR   DepMap; ACH-001650
DR   DSMZ; ACC-327
DR   DSMZCellDive; ACC-327
DR   EGA; EGAS00001000978
DR   GDSC; 1240212
DR   GEO; GSM1670424
DR   LINCS_LDP; LCL-1514
DR   PharmacoDB; SISO_1379_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_2193
DR   Wikidata; Q54953520
RX   PubMed=21556646;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35692560;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 24 hours (PubMed=21556646); ~35 hours (DSMZ=ACC-327).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser834Ter (c.2501C>G); ClinVar=VCV000428733; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.91%; Native American=0.11%; East Asian, North=79.2%; East Asian, South=9.59%; South Asian=0%; European, North=0%; European, South=7.19% (PubMed=30894373).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 14,16
ST   D19S433: 14 (DSMZ)
ST   D19S433: 14,16.2 (PubMed=25877200)
ST   D21S11: 30,31
ST   D2S1338: 19
ST   D3S1358: 15
ST   D5S818: 9,12
ST   D7S820: 11,12
ST   D8S1179: 12
ST   FGA: 23
ST   Penta D: 11,13
ST   Penta E: 11,13
ST   TH01: 7 (PubMed=25877200)
ST   TH01: 7,9 (Cosmic-CLP; DepMap; DSMZ)
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=21556646; DOI=10.3892/ijo.6.5.1099;
RA   Sonoda K., Nakashima M., Saito T., Amada S., Kamura T., Nakano H.,
RA   Watanabe T.;
RT   "Establishment of a new human uterine cervical adenocarcinoma cell-line,
RT   SiSo, and its reactivity to anticancer reagents.";
RL   Int. J. Oncol. 6:1099-1104(1995).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35692560; DOI=10.1080/23723556.2022.2078628;
RA   de Lourdes Zuniga-Martinez M., Lopez-Mendoza C.M., Tenorio-Salazar J.,
RA   Garcia-Carranca A.M., Cerbon-Cervantes M.A., Alcantara-Quintana L.E.;
RT   "Establishment, authenticity, and characterization of cervical cancer
RT   cell lines.";
RL   Mol. Cell. Oncol. 9:2078628.1-2078628.10(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//